| 2022 | A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naive, high-risk essential thrombocythemia as a primary treatment | 문영철 | Article |
| 2016 | Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients | 문영철 | Article |
| 2019 | Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System | 문영철 | Article |
| 2015 | Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial | 문영철 | Meeting Abstract |
| 2012 | Head-to-Head Comparison of 5-Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndrome | 문영철 | Meeting Abstract |
| 2016 | Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study | 문영철 | Article |
| 2020 | Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE) | 문영철 | Article |
| 2015 | Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia | 문영철 | Article |
| 2015 | Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib | 문영철 | Meeting Abstract |
| 2016 | Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome | 성주명; 문영철 | Article |
| 2012 | Restrospective Multicenter Study Evaluating Efficacy and Safety of Dasatinib and Nilotinib in Patients with Imatinib-Resistant or -intolerant Chronic Myeloid Leukemia in Chronic Phase: Korean CML Working Party | 성주명 | Meeting Abstract |
| 2014 | Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma | 박상희 | Article |
| 2021 | The 2020 revision of the guidelines for the management of myeloproliferative neoplasms | 문영철 | Review |
